2月28日 - ** 经纪公司雷蒙德-詹姆斯（Raymond James）恢复对制药商桥生制药BBIO.O的评级，给予 "跑赢大盘 "评级；将目标价定为57美元，较该股上次收盘价上涨66.4%。
** 券商预计，BBIO推出心脏病药物Attruby的速度将快于预期，即使由于辉瑞PFE.N的tafamidis失去独家代理权而面临潜在的定价压力，BBIO在2028年后的收入将大幅打折扣。
** 券商补充说："我们预计它将在新诊断人群中获得可观的市场份额。
** BBIO可以利用其药物Encaleret和BBP-418建立合作伙伴关系并改善财务状况--经纪商
** 根据 LSEG 编制的数据，16 家券商中有 14 家给予该股 "买入 "或更高评级，2 家给予 "持有 "评级
** 过去 12 个月股价下跌了 4.1
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.